Lannett Company, Inc. announced that its board of directors has named Timothy C. Crew as the company's chief executive officer (CEO), effective January 2, 2018. The Board of Directors intends to appoint Crew as a director of the company after completion of its 2018 Annual Meeting of Stockholders. Crew will succeed Arthur Bedrosian, who will continue to serve as CEO until Crew joins the company.

Crew has more than 25 years of experience in the generic and branded pharmaceutical industries, most recently serving as CEO of Cipla North America, from 2013 to 2017. Previously, he worked for eight years at Teva Pharmaceuticals, where he served as Senior Vice President and Commercial Operating Officer of the North American Generics division.